Juvenile-Onset Recurrent Rhabdomyolysis Due to Compound Heterozygote Variants in the ACADVL Gene.
Beatrice LabellaGaetana LanziStefano Cotti PiccinelliFilomena CariaSimona DamioliBarbara RisiEnrica BertellaLoris PoliAlessandro PadovaniMassimiliano MirabellaPublished in: Brain sciences (2023)
Very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency is a rare autosomal recessive long-chain fatty acid oxidation disorder caused by mutations in the ACADVL gene. The myopathic form presents with exercise intolerance, exercise-related rhabdomyolysis, and muscle pain, usually starting during adolescence or adulthood. We report on a 17-year-old boy who has presented with exercise-induced muscle pain and fatigue since childhood. In recent clinical history, episodes of exercise-related severe hyperCKemia and myoglobinuria were reported. Electromyography was normal, and a muscle biopsy showed only "moth-eaten" fibers, and a mild increase in lipid storage in muscle fibers. NGS analysis displayed the already known heterozygote c.1769G>A variant and the unreported heterozygote c.523G>C change in ACADVL both having disease-causing predictions. Plasma acylcarnitine profiles revealed high long-chain acylcarnitine species levels, especially C14:1. Clinical, histopathological, biochemical, and genetic tests supported the diagnosis of VLCAD deficiency. Our report of a novel pathogenic missense variant in ACADVL expands the allelic heterogeneity of the disease. Since dietary treatment is the only therapy available for treating VLCAD deficiency and it is more useful the earlier it is started, prompt diagnosis is essential in order to minimize muscle damage and slow the disease progression.
Keyphrases
- fatty acid
- skeletal muscle
- copy number
- high intensity
- acute kidney injury
- chronic pain
- genome wide
- physical activity
- depressive symptoms
- replacement therapy
- neuropathic pain
- oxidative stress
- stem cells
- intellectual disability
- single cell
- resistance training
- gene expression
- bone marrow
- ultrasound guided
- drug induced
- genome wide identification
- cell therapy